Here are four things to know:
1. The system is aimed to improve patients’ postoperative primary total knee arthroplasty rehabilitation and reduce associated postacute care costs.
2. CyMedica President and CEO Rob Morocco said, “This clinical trial will allow us to accelerate what we believe is an essential shift in the care model for total knee post-surgical rehabilitation.”
3. The device addresses the issues associated with patients’ lack of quadriceps strength after knee surgery.
4. Patients often have to pay up to $4,200 to treat post-surgical muscle atrophy with rehabilitation and have a higher likelihood of readmissions.
More articles on devices:
Baxter highlights FLOSEAL hemostatic agent enhancements for spine, cardiac surgery: 5 highlights
Implanet intends to transfer share listing from Euronext to Alternext Paris: 5 key notes
Spinal implant 3D printing: 5 findings from 2 key cases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
